Abstract
THE first step in infection by the human immunodeficiency virus (HIV) is the specific binding of gp!20, the envelope glycoprotein of HIV, to its cellular receptor, CD4 (see ref. 1 for review). To inhibit this interaction, soluble CD4 analogues that compete for gp120 binding and block HIV infection in vitro have been developed2–8. To determine whether these analogues can protect an uninfected individual from challenge with HIV, we used the chimpanzee model system of cell-free HIV infection. Chimpanzees are readily infected with the IIIB strain of HIV-1, becoming viraemic within about 4–6 weeks of challenge, although they do not develop the profound CD4+ T-cell depletion and immunodeficiency characteristic of HIV infection in humans9. CD4 immunoadhesin (CD4–IgG), a chimaeric molecule consisting of the N-terminal two immunoglobulin-like regions of CD4 joined to the Fc region of human IgG1 (refs 8, 10), was selected as the CD4 analogue for testing because it has a longer half-life than CD4, contributed by the IgG Fc portion of the molecule. In humans, this difference results in a 25-fold increased concentration of CD4–IgG in the blood compared with recombinant CD4 (ref. 11). Here we report that pretreatment with CD4–IgG can prevent the infection of chimpanzees with HIV-1. The need for a preventative agent is particularly acute in perinatal HIV transmission. As recombinant CD4–IgG, like the parent IgG molecule, efficiently crosses the primate placenta10, it may be possible to set up an immune state in a fetus before HIV transfer occurs, thus preventing infection.
Similar content being viewed by others
Article PDF
References
Capon, D. & Ward, R. H. R. A. Rev. Immun. 9, 649–678 (1991).
Smith, D. H. et al. Science 328, 1704–1707 (1987).
Fisher, R. et al. Nature 331, 76–78 (1988).
Hussey, R. et al. Nature 331, 78–81 (1988).
Deen, K. et al. Nature 331, 82–84 (1988).
Traunecker, A., Luke, W. & Karjalainen, K. Nature 331, 84–86 (1988).
Berger, E., Fuerst, T. & Moss, B. Proc. natn. Acad Sci. U.S.A. 85, 2357–2361 (1988).
Capon, D. et al. Nature 337, 525–531 (1989).
Eichberg, J. W. in Animal Models in AIDS (eds Schellekens, H. & Horzinek, M. C.) 47–52 (Elsevier, Amsterdam, 1990).
Byrn, R. et al. Nature 344, 667–670 (1990).
Mordenti, J., Chen, S. A., Moore, J. A., Ferraiolo, B. & Green, J. D. Pharmac. Res. (in the press).
Hu, S.-L. et al. Nature 328, 721–723 (1987).
Berman, P. W. et al. Nature 345, 622–625 (1990).
Girard, M. et al. Proc. natn. Acad. Sci. U.S.A. 88, 542–546 (1991).
McCune, J. M., Namikawa, R., Shih, C. C., Rabin, L. & Kaneshima, H. Science 247, 564–566 (1990).
Marrin, L. N., Murphey-Corb, M., Soike, K. F. & Davidson-Fairburn, B. 8th A. Symp. Nonhuman Primate Models for AIDS 56 (Delta Regional Primate Research Center, Tulane University, 1990).
Lange, J. M. A. et al. New Engl. J. Med. 322, 1375–1377 (1990).
Bernard, N. et al. New Engl. J. Med. 323, 916 (1990).
Daar, E. S., Li, X. L., Moudgli, T. & Ho, D. D. Proc. natn. Acad. Sci. U.S.A. 87, 6574–6578 (1990).
Blanche, S. et al. New Engl. J. Med. 320, 1643–1648 (1989).
Thompson, G. & Shumaker, R. Drug Metabolism Rev. 21, 463–469 (1989).
Anderson, K. P. et al. J. Infect. Dis. 160, 960–969 (1989).
Saiki, R. K. et al. Science 230, 487–491 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ward, R., Capon, D., Jett, C. et al. Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin. Nature 352, 434–436 (1991). https://doi.org/10.1038/352434a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/352434a0
This article is cited by
-
Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase
Nature Medicine (1997)
-
The HIV gp120-CD4 interaction: A target for pharmacological or immunological intervention?
Perspectives in Drug Discovery and Design (1993)
-
Characterization and anti-HIV properties of CD 4-coated red blood cells
Archives of Virology (1992)
-
Passive primate protection
Nature (1991)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.